Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 8 Mar 2013 |
| CORRECTION: Notice of Zealand Pharma Full Year results and publication of the Annual Report for 2012 | 8 Mar 2013 |
| Zealand Pharma A/S New Articles of Association following issue of new warrant program | 21 Feb 2013 |
| Zealand Pharma’s partner Sanofi has announced a New Drug Application for lixisenatide in the US accepted for review by FDA | 19 Feb 2013 |
| Zealand Pharma announces grant of warrants to employees under existing incentive scheme | 8 Feb 2013 |